Celltrion Healthcare, 'Entering Full-Scale Earnings Growth Trajectory' Stock Price at 97,500 KRW (2.31%)

As of 11:10 AM on the 18th, Celltrion Healthcare is trading at 97,500 KRW, up 2.31% from the previous day. The trading volume is 2,735,391 shares, which is about 85.41% of the previous day's volume. Celltrion Healthcare is known as the exclusive distributor of Celltrion's biosimilars.

On May 18, NH Investment & Securities analyst Koo Wan-sung maintained a "Top-pick" rating for the bio sector. As of March, Truxima's market share in the U.S. reached approximately 8%. The company's assumption for Truxima's U.S. market share this year was revised from 7.3% to 11.3% (2021: 13.3% → 15.3%). Remsima SC recorded its first direct sales revenue in Europe of about 7.1 billion KRW. With all indications expected to be approved in the second half of the year, Remsima SC prescriptions are anticipated to accelerate, and the increase in direct sales proportion is expected to further improve profitability. Accordingly, the target price for Celltrion Healthcare was set at 110,000 KRW.

Over the past five days, individual investors have net sold 416,684 shares of Celltrion Healthcare, while foreigners and institutions have net sold 94,884 shares and net bought 516,599 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.